key: cord-0707964-tony3g0q
authors: Hasan Ali, Omar; Bomze, David; Risch, Lorenz; Brugger, Silvio D; Paprotny, Matthias; Weber, Myriam; Thiel, Sarah; Kern, Lukas; Albrich, Werner C; Kohler, Philipp; Kahlert, Christian R; Vernazza, Pietro; Bühler, Philipp K; Schüpbach, Reto A; Gómez-Mejia, Alejandro; Popa, Alexandra M; Bergthaler, Andreas; Penninger, Josef M; Flatz, Lukas
title: Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies
date: 2020-09-30
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1496
sha: 6d6d798953b7f19abe81da7677bc8eff403152e3
doc_id: 707964
cord_uid: tony3g0q

BACKGROUND: Severe coronavirus disease 2019 (COVID-19) frequently entails complications that bear similarities to autoimmune diseases. To date, there is little data on possible IgA-mediated autoimmune responses. Here, we aim to determine whether COVID-19 is associated with a vigorous total IgA response and if IgA antibodies are associated with complications of severe illness. Since thrombotic events are frequent in severe COVID-19 and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused on antiphospholipid antibodies (aPL). METHODS: In this retrospective cohort study clinical data and aPL from 64 patients with COVID-19 were compared from three independent tertiary hospitals (one in Liechtenstein, two in Switzerland). Samples were collected from April 9 (th) to May 1 (st), 2020. RESULTS: Clinical records of 64 patients with COVID-19 were reviewed and divided into a cohort with mild illness (mCOVID) (41%), a discovery cohort with severe illness (sdCOVID) (22%) and a confirmation cohort with severe illness (scCOVID) (38%). Total IgA, IgG and aPL were measured with clinical diagnostic kits. Severe illness was significantly associated with increased total IgA (sdCOVID, P=0.01; scCOVID, p-value<0.001), but not total IgG. Among aPL, both cohorts with severe illness significantly correlated with elevated anti-Cardiolipin IgA (sdCOVID and scCOVID, p-value<0.001), anti-Cardiolipin IgM (sdCOVID, P=0.003; scCOVID, P<0.001), and anti-Beta2 Glycoprotein-1 IgA (sdCOVID and scCOVID, P<0.001). Systemic lupus erythematosus was excluded from all patients as a potential confounder. CONCLUSIONS: Higher total IgA and IgA-aPL were consistently associated with severe illness. These novel data strongly suggest that a vigorous antiviral IgA-response, possibly triggered in the bronchial mucosa, induces systemic autoimmunity.

The novel coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic with wideranging health and socio-economic implications. After SARS and the Middle East Respiratory Syndrome, it represents the third known spillover of a severe coronavirus-associated disease from animals to humans in the last twenty years [1] [2] [3] . SARS-CoV-2 enters human cells by attachment to and subsequent internalization of Angiotensin-converting enzyme 2 receptors that are highly expressed by type-II pneumocytes in the deep bronchial system [4] , where IgA immunoglobulins produced in the bronchial-associated lymphoid tissue (BALT) are the main line of humoral defense [5] . Indeed, specific IgA against the SARS-CoV-2 spike protein have been shown to appear early in infected patients [6] . However, despite the important role of IgA in mucosal immunity, the rate of total IgA generated by that response and its role in COVID-19 severity remains unexplored.

Autopsies have shown acute respiratory distress syndrome (ARDS) and sepsis to be the most common complications in critically-ill COVID-19 patients [7] . A large case series from Northern Italy that assessed lung histologies of deceased COVID-19 patients present consistent diffuse alveolar damage and necrosis of pneumocytes [8] . A distinctive factor for COVID-19 was a marked presence of diffuse thrombosis of the peripheral small vessels. This is in line with reports of frequent thromboembolisms of patients with severe COVID-19 that occur despite the prophylactic in-hospital use of low weight molecular heparins [9, 10] . While the reasons remain unclear, a recent report describes a case series of severe COVID-19 patients with stroke and elevated levels of antiphospholipid (aPL) antibodies compatible with antiphospholipid syndrome (APS) [11] . APS is an acquired A c c e p t e d M a n u s c r i p t 8 autoimmune disease that is mediated by autoantibodies directed against phospholipid-binding proteins that leads to hypercoagulability. The most common trigger factor of APS is systemic lupus erythematosus (SLE), followed by lung infections with mycobacteria or viruses [12] . These cases suggest that COVID-19 leads to virally triggered APS in severe COVID-19 patients. To our knowledge, complete aPL profiling in mild and severe cases of COVID-19 has never been undertaken. The aim of this study was to explore, whether patients with severe COVID-19 have elevated total IgA as an immediate immune response and aPL compatible with APS.

The multicenter cohort study was conducted at the Landesspital Liechtenstein (LLS) in Vaduz, Liechtenstein, the Kantonsspital St. Gallen (KSSG) in St. Gallen, Switzerland, and the University Hospital Zurich (USZ) in Zurich, Switzerland, in accordance with the Declaration of Helsinki guidelines. The collection of patient data and blood samples was approved by the respective local ethics committees of the participating study centers (Project-IDs 2020-00676, 2020-00821, and 2020-00646). All participants agreed to the hospitals' general consent policies allowing further use of clinical data and biologic material (LLS and KSSG) or signed an informed consent (USZ). Where signing of informed consent was not possible due to severe illness and to prevent surface contamination, consent was sought verbally or from the next of kin, which had been approved by the respective local ethics committee.

A c c e p t e d M a n u s c r i p t 9 Patient data and sample collection:

Collection of patient data and samples (serum or plasma) was conducted from April 9, 2020, to May 1, 2020. All samples were obtained within two weeks of symptom onset. Patients with SARS-CoV-2 infection were included that had been confirmed by either real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of nasopharyngeal swab samples or serology. The methods of RT-PCR used to detect SARS-CoV-2 depended on the study center and were performed as previously described [13, 14] . For confirmation with serology SARS-CoV-2 antibodies were analyzed by two independent antibody tests: a lateral flow immunochromatographic assay (LFIA, gold nanoparticle-based, SGIT flex Covid 19) (Sugentech, Daejeon, South Korea) and an electro-chemiluminescence immunoassay (ECLIA, Elecsys Anti-SARS-CoV-2) (Roche International Diagnostics AG, Rotkreuz, Switzerland). Seropositivity was defined as a positive IgM signal in the LFIA in the acute phase that was confirmed by IgG in the ECLIA after 3-4 weeks.

Patients were categorized into the following cohorts: 1. mild illness without requirement of hospitalization (mCOVID) which were collected at the LLS, 2. a discovery cohort of patients with severe illness (sdCOVID) obtained at the USZ, and 3. an independent confirmation cohort of patients with severe illness (scCOVID) from the KSSG. Mild illness was defined as uncomplicated upper respiratory tract infection with unspecific symptoms or uncomplicated pneumonia, while severe illness for the sdCOVID and scCOVID cohorts required hospitalization and included severe pneumonia, ARDS, and septic shock [15] . 

Point estimates of autoantibody levels were described using the mean and the standard error of the mean. Differences in autoantibody levels between cohorts were assessed using the nonparametric Mann-Whitney test. All P-values were adjusted for multiple hypothesis testing using the false discovery rate (FDR) method. Statistical significance was defined at the level of FDR <0.05. All analyses were performed using R software, version 3. Table 1 .

Severely ill COVID-19 patients had significantly higher total IgA titers compared to mCOVID patients (sdCOVID, mean 2.94 g/l, SD ±0.46, P=0.01; scCOVID mean 3.04 g/l, SD ±0.19, Since APS is commonly triggered by SLE serology screening was performed for all patients, as described in the methods section. One patient from the scCOVID cohort had elevated anti-La IgG (7.4 U/ml, normal < 1 U/ml) but no other lupus-specific antibodies. None of the other patients were positive for any SLE-associated antibodies.

In this study we measured total IgA and IgG, as well as aPL in COVID-19 patients of similar age and compared the results of mildly ill with severely ill patients from independent tertiary care health care centers. For severely ill patients we established a discovery and A c c e p t e d M a n u s c r i p t 13 investigation cohort. Our novel finding shows a marked elevation of total IgA that is significantly associated with severe COVID-19, which to our knowledge has not been reported before. There is no significant association with total IgG. These data support our hypothesis, that a strong, IgA-driven immune response possibly emerges from the BALT when SARS-CoV-2 affects the deeper respiratory system [16] . In line with literature, about a third of severely ill patients developed thromboses [10] that did not correlate with d-dimer levels [17, 18] . These thromboses may be explained by an elevation of total IgA and aPL IgA antibodies, which we found to be significantly associated with severe illness. This correlation could neither be seen for total IgG, nor for aPL IgG antibodies. While an association of elevated aPL and severe COVID-19 has been suggested [19] , the elevation of total IgA together with IgA-aPL when comparing mild and severe COVID-19 is novel and draws the missing link between immune response and hypercoagulation, as it strongly suggests induction of IgA-dominated APS. APS is most commonly triggered by SLE [12] , which was excluded in all patients through serological screening [20] . Another potential trigger of APS is infection, including pneumonia, that leads to autoimmunity via molecular mimicry [21] [22] [23] . In the case of COVID-19 such a mechanism may be mediated by pulmonary surfactant, as it is rich in phospholipid-binding proteins [24] . Surfactant is produced by type-II pneumocytes, which express high levels of ACE-2 receptors and are a primary target of SARS-CoV-2 [8, 25] . Pneumocyte necrosis leads to surfactant leakage, exposing phospholipid proteins to the immune system. It is feasible that peptide commonalities between SARS-CoV-2 and surfactant proteins induce APS. Indeed, a high coverage of such peptide commonalities has recently been demonstrated by Kanduc D. et al., who found that almost half of the immunoreactive epitopes on the spike glycoprotein of SARS-CoV-2 share pentapeptides on human surfactant-related proteins [26] . In practice, preliminary results of the COVID-19 therapy (RECOVERY) trial demonstrate a significant benefit of dexamethasone therapy for severely ill patients [27] , further suggesting an important role of immune exacerbation in COVID-19 related deaths. The effects of aPL could be further enhanced by toll-like receptor-4, which is upregulated in patients with SARS [28] and has been shown to enhance A c c e p t e d M a n u s c r i p t 14 hypercoagulation [29] . Importantly, these data support a link between IgA and Kawasaki disease-like multisystem inflammatory syndrome in children (MIS-C). MIS-C is a novel COVID-19 related disease that shows significant overlaps with classical Kawasaki disease (KD) but has a later onset and tends to be more severe [30, 31] . Interestingly, classical KD is most commonly associated with respiratory viruses [32] and rare severe KD has been shown to be associated with organ deposits of IgA-producing plasma cells [33, 34] . This suggests that elevated total IgA may have a causal role in MIS-C.

Main limitations of the study are its cohort sizes and retrospective design. Furthermore, the study does not include longitudinal measurements of antibodies. Due to an inconsistent availability of data on past history of thrombosis, pro-inflammatory cytokines and clinical outcome, these factors could not be considered. Furthermore, C-reactive protein and ddimer levels were only available from the severely ill cohorts. Nevertheless, the inclusion of cohorts from independent health care centers, as well as a discovery and a confirmation cohort of patients with severe COVID-19 from different hospitals for additional validation are major strengths of the study.

In conclusion, we present a novel significant association between severe COVID-19, 

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Molecular Pathogenesis of Middle East Respiratory Syndrome (MERS) Coronavirus

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Immune functions and immunopathology of the mucosa of the upper respiratory pathways

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Covid-19 and thrombosis: what do we know about the risks and treatment?

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Antiphospholipid syndrome

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system

Clinical Management of COVID-19: interim guidance

Lung mucosal immunity: immunoglobulin-A revisited

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients

European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

Infectious origin of the antiphospholipid syndrome

Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients

Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant)

Surfactant Lipids at the Host-Environment Interface. Metabolic Sensors, Suppressors, and Effectors of Inflammatory Lung Disease

An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease

On the molecular determinants of the SARS-CoV-2 attack

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury

Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Dissecting Kawasaki disease: a stateof-the-art review

IgA plasma cells in vascular tissue of patients with Kawasaki syndrome

IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease

We thank Dorothea Hillmann and Francesca Ferrara (both from Labormedizinisches Zentrum Dr. Risch) for their laboratory analysis contributions.Funding: